Molecular Imaging and Therapy of Prostate Cancer
Experts from the Society of Nuclear Medicine and Molecular Imaging will speak on the most advanced nuclear medicine technology in both the imaging and therapy of prostate cancer. Prostate specific membrane antigen (PSMA) has been extensively studied as both an imaging and therapeutic target for prostate cancer and therefore also as a theranostic target. PSMA-targeted radiopharmaceuticals for PET imaging and for delivery of therapeutic radiation are now in phase 3 trials and thus may soon be available to greatly expand the role of nuclear medicine in the care of patients with prostate cancer.
Earn credit at your own pace through June 4, 2023 and continue to access your videos until June 5, 2030. See below for learning outcomes and a list of modules and individual lectures.
This course offers 2 CME and SA-CME Credits following completion of an online assessment.
ARRS Member price: FREE
ARRS In-Training Member price: FREE
Nonmember price: $399
Video content for this Online Course will be available to view until June 5, 2030, which is ten years following the issuance date of this course. ARRS reserves the right to remove video content before the end of the ten year period. Video content that contradicts current science or misleads the viewer based on changes to accepted clinical practice may be removed on a case-by-case basis.
Learning Outcomes and Modules
After completing this course, the learner should be able to:
- describe the capabilities of PSMA-PET imaging for prostate cancer
- discuss PSMA targeted PET interpretation
- discuss clinical indications for ordering of fluciclovine-PET
- Mastering the Interpretation of Fluciclovine-PET—S. Galgano
- PSMA-targeted PET Imaging for Prostate Cancer—K. Zukotynski
- Theranostics for Prostate Cancer—P. Kuo
View the sample recording below
The American Roentgen Ray Society (ARRS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
The ARRS designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit(s)™
and 2.00 American Board of Radiology
, MOC Part II, Self-Assessment CME (SA-CME) credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.